BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dutta U. Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol. 2012;27:642-653. [PMID: 22168580 DOI: 10.1111/j.1440-1746.2011.07048.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
Number Citing Articles
1 Kazmi HR, Chandra A, Kumar S, Satyam LK, Gupta A, Nigam J, Srivastava M, Mittal B. A let-7 microRNA binding site polymorphism in the KRAS 3′UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population. J Cancer Res Clin Oncol 2016;142:2577-83. [DOI: 10.1007/s00432-016-2254-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
2 Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99-109. [PMID: 24634588 DOI: 10.2147/clep.s37357clep-6-099] [Reference Citation Analysis]
3 Hari DM, Howard JH, Leung AM, Chui CG, Sim MS, Bilchik AJ. A 21-year analysis of stage I gallbladder carcinoma: is cholecystectomy alone adequate? HPB (Oxford). 2013;15:40-48. [PMID: 23216778 DOI: 10.1111/j.1477-2574.2012.00559.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
4 Kattepur AK, Patkar S, Goel M, Ramaswamy A, Ostwal V. Role of Adjuvant Chemotherapy in Resected T2N0 Gall Bladder Cancer. J Gastrointest Surg 2019;23:2232-8. [DOI: 10.1007/s11605-019-04104-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
5 Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99-109. [PMID: 24634588 DOI: 10.2147/clep.s37357.] [Reference Citation Analysis]
6 Chang Y, Liu C, Yang J, Liu G, Feng F, Tang J, Hu L, Li L, Jiang F, Chen C. MiR-20a triggers metastasis of gallbladder carcinoma. J Hepatol. 2013;59:518-527. [PMID: 23665284 DOI: 10.1016/j.jhep.2013.04.034] [Cited by in Crossref: 85] [Cited by in F6Publishing: 72] [Article Influence: 10.6] [Reference Citation Analysis]
7 Ma F, Zhang M, Gong W, Weng M, Quan Z. MiR-138 Suppresses Cell Proliferation by Targeting Bag-1 in Gallbladder Carcinoma. PLoS One. 2015;10:e0126499. [PMID: 25962180 DOI: 10.1371/journal.pone.0126499] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
8 Patil RS, Shah SU, Shrikhande SV, Goel M, Dikshit RP, Chiplunkar SV. IL17 producing γδT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. Int J Cancer 2016;139:869-81. [PMID: 27062572 DOI: 10.1002/ijc.30134] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 11.8] [Reference Citation Analysis]
9 Wang J, Ni X, Shen S, Zhang D, Ni X, Suo T, Lu P, Fan K, Liu H, Liu H. Phosphorylation at Ser10 triggered p27 degradation and promoted gallbladder carcinoma cell migration and invasion by regulating stathmin1 under glucose deficiency. Cell Signal 2021;80:109923. [PMID: 33444777 DOI: 10.1016/j.cellsig.2021.109923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016;22:10254-9. [PMID: 28028375 DOI: 10.3748/wjg.v22.i46.10254] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
11 Wei D, Zhang X, Zou H, Wang L, Fu B, Wu X, Luo Z, Li X, Ge J, Li Y, Zhu H, Wang K, Wang T, Yang P, Hou Z, Wang W. WW domain containing oxidoreductase induces apoptosis in gallbladder-derived malignant cell by upregulating expression of P73 and PUMA. Tumour Biol 2014;35:1539-50. [PMID: 24127039 DOI: 10.1007/s13277-013-1213-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
12 Nakada S, Kuboki S, Nojima H, Yoshitomi H, Furukawa K, Takayashiki T, Takano S, Miyazaki M, Ohtsuka M. Roles of Pin1 as a Key Molecule for EMT Induction by Activation of STAT3 and NF-κB in Human Gallbladder Cancer. Ann Surg Oncol 2019;26:907-17. [PMID: 30610554 DOI: 10.1245/s10434-018-07132-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
13 Chen LD, Huang Y, Xie XH, Chen W, Shan QY, Xu M, Liu JY, Nie ZQ, Xie XY, Lu MD, Shen SL, Wang W. Diagnostic nomogram for gallbladder wall thickening mimicking malignancy: using contrast-enhanced ultrasonography or multi-detector computed tomography? Abdom Radiol (NY). 2017;42:2436-2446. [PMID: 28447109 DOI: 10.1007/s00261-017-1162-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
14 Zhang F, Li M, Wu X, Hu Y, Cao Y, Wang X, Xiang S, Li H, Jiang L, Tan Z, Lu W, Weng H, Shu Y, Gong W, Wang X, Zhang Y, Shi W, Dong P, Gu J, Liu Y. 20(S)-ginsenoside Rg3 promotes senescence and apoptosis in gallbladder cancer cells via the p53 pathway. Drug Des Devel Ther 2015;9:3969-87. [PMID: 26309394 DOI: 10.2147/DDDT.S84527] [Cited by in Crossref: 3] [Cited by in F6Publishing: 29] [Article Influence: 0.5] [Reference Citation Analysis]
15 Shen H, He M, Lin R, Zhan M, Xu S, Huang X, Xu C, Chen W, Yao Y, Mohan M, Wang J. PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway. J Exp Clin Cancer Res 2019;38:247. [PMID: 31182136 DOI: 10.1186/s13046-019-1250-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
16 Arumugam P, Balarajah V, Watt J, Abraham AT, Bhattacharya S, Kocher HM. Role of laparoscopy in hepatobiliary malignancies. Indian J Med Res 2016;143:414-9. [PMID: 27377496 DOI: 10.4103/0971-5916.184300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
17 Weng M, Gong W, Ma M, Chu B, Qin Y, Zhang M, Lun X, McFadden G, Forsyth P, Yang Y, Quan Z. Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo. Mol Cancer 2014;13:82. [PMID: 24725816 DOI: 10.1186/1476-4598-13-82] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
18 Li G, Pu Y. MicroRNA signatures in total peripheral blood of gallbladder cancer patients. Tumour Biol. 2015;36:6985-6990. [PMID: 25861754 DOI: 10.1007/s13277-015-3412-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
19 Wasnik AP, Davenport MS, Kaza RK, Weadock WJ, Udager A, Keshavarzi N, Nan B, Maturen KE. Diagnostic accuracy of MDCT in differentiating gallbladder cancer from acute and xanthogranulomatous cholecystitis. Clin Imaging. 2018;50:223-228. [PMID: 29679780 DOI: 10.1016/j.clinimag.2018.04.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
20 Wang J, Pan Y, Hu J, Ma Q, Xu Y, Zhang Y, Zhang F, Liu Y. Tea polyphenols induce S phase arrest and apoptosis in gallbladder cancer cells. Braz J Med Biol Res 2018;51:e6891. [PMID: 29513793 DOI: 10.1590/1414-431X20176891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
21 Rakić M, Patrlj L, Kopljar M, Kliček R, Kolovrat M, Loncar B, Busic Z. Gallbladder cancer. Hepatobiliary Surg Nutr 2014;3:221-6. [PMID: 25392833 DOI: 10.3978/j.issn.2304-3881.2014.09.03] [Cited by in F6Publishing: 57] [Reference Citation Analysis]
22 Jain K, Sreenivas V, Velpandian T, Kapil U, Garg PK. Risk factors for gallbladder cancer: a case-control study. Int J Cancer. 2013;132:1660-1666. [PMID: 22890893 DOI: 10.1002/ijc.27777] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
23 Shen S, Wang JW, Zheng BH, Ni XJ, Gao ZH, Zhang DX, Lu PX, Ni XL, Suo T, Liu HB, Liu H. The lnc-CITED2-2:1 inhibits metastasis via inhibiting CITED2 and epithelial-mesenchymal transition in gallbladder cancer. Clin Transl Med 2020;10:e116. [PMID: 32578934 DOI: 10.1002/ctm2.116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Liu S, Chu B, Cai C, Wu X, Yao W, Wu Z, Yang Z, Li F, Liu Y, Dong P, Gong W. DGCR5 Promotes Gallbladder Cancer by Sponging MiR-3619-5p via MEK/ERK1/2 and JNK/p38 MAPK Pathways. J Cancer 2020;11:5466-77. [PMID: 32742494 DOI: 10.7150/jca.46351] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
25 Fan K, Wang J, Sun W, Shen S, Ni X, Gong Z, Zheng B, Gao Z, Ni X, Suo T, Liu H, Liu H. MUC16 C-terminal binding with ALDOC disrupts the ability of ALDOC to sense glucose and promotes gallbladder carcinoma growth. Exp Cell Res 2020;394:112118. [PMID: 32502493 DOI: 10.1016/j.yexcr.2020.112118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
26 Ying H, Fengying S, Feng H, Yanhong W, Xianru X, Xiaolei T. Diagnostic value of quantification of circulating free DNA for gall bladder cancer using a chemiluminescence DNA biosensor system based on DNA G-quadruplex/ hemin enzyme. Transl Oncol 2021;14:100928. [PMID: 33212417 DOI: 10.1016/j.tranon.2020.100928] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Wang S, Liu C, Liu X, He Y, Shen D, Luo Q, Dong Y, Dong H, Pang Z. Effects of matrix metalloproteinase inhibitor doxycycline and CD147 antagonist peptide-9 on gallbladder carcinoma cell lines. Tumour Biol 2017;39:1010428317718192. [PMID: 29034777 DOI: 10.1177/1010428317718192] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
28 Yang G, Xu Q, Wan Y, Zhang L, Wang Z, Meng F. miR-193a-3p Enhanced the Chemosensitivity to Trametinib in Gallbladder Carcinoma by Targeting KRAS and Downregulating ERK Signaling. Cancer Biother Radiopharm 2021. [PMID: 34287012 DOI: 10.1089/cbr.2021.0016] [Reference Citation Analysis]
29 Zhang ZG, Chen Y, Ji R, Zhao YJ, Wang J, Robinson L, Chen XP, Zhang L. Synchronous cancers of gallbladder carcinoma and combined hepatocellular cholangiocarcinoma: an unusual case and literature review. BMC Cancer. 2018;18:1046. [PMID: 30373546 DOI: 10.1186/s12885-018-4969-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
30 Tian L, Lu Y, Yang T, Deng Z, Xu L, Yao W, Ma C, Li X, Zhang J, Liu Y, Wang J. aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1. Redox Biol 2019;22:101149. [PMID: 30822690 DOI: 10.1016/j.redox.2019.101149] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
31 Yang XW, Yang J, Li L, Man XB, Zhang BH, Shen F, Wu MC. Analysis of the relationships between clinicopathologic factors and survival in gallbladder cancer following surgical resection with curative intent. PLoS One. 2012;7:e51513. [PMID: 23300551 DOI: 10.1371/journal.pone.0051513] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
32 Jaruvongvanich V, Yang JD, Peeraphatdit T, Roberts LR. The incidence rates and survival of gallbladder cancer in the USA. European Journal of Cancer Prevention 2019;28:1-9. [DOI: 10.1097/cej.0000000000000402] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
33 Zhang GF, Wu JC, Wang HY, Jiang WD, Qiu L. Overexpression of microRNA-205-5p exerts suppressive effects on stem cell drug resistance in gallbladder cancer by down-regulating PRKCE. Biosci Rep 2020;40:BSR20194509. [PMID: 32869841 DOI: 10.1042/BSR20194509] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Li Y, Zhang J, Ma H. Chronic inflammation and gallbladder cancer. Cancer Lett. 2014;345:242-248. [PMID: 23981574 DOI: 10.1016/j.canlet.2013.08.034] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
35 Ma Q, Zhang Y, Liang H, Zhang F, Liu F, Chen S, Hu Y, Jiang L, Hao Y, Li M, Liu Y. EMP3, which is regulated by miR-663a, suppresses gallbladder cancer progression via interference with the MAPK/ERK pathway. Cancer Letters 2018;430:97-108. [DOI: 10.1016/j.canlet.2018.05.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
36 Xu G, Wei X, Tu Q, Zhou C. Up-regulated microRNA-33b inhibits epithelial-mesenchymal transition in gallbladder cancer through down-regulating CROCC. Biosci Rep 2020;40:BSR20190108. [PMID: 31799620 DOI: 10.1042/BSR20190108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Sun DP, Lin CY, Tian YF, Chen LT, Lin LC, Lee SW, Hsing CH, Lee HH, Shiue YL, Huang HY. Clinicopathological significance of HuR expression in gallbladder carcinoma: with special emphasis on the implications of its nuclear and cytoplasmic expression. Tumour Biol. 2013;34:3059-3069. [PMID: 23722602 DOI: 10.1007/s13277-013-0872-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
38 Zhu JQ, Han DD, Li XL, Kou JT, Fan H, He Q. Predictors of incidental gallbladder cancer in elderly patients. Hepatobiliary Pancreat Dis Int 2015;14:96-100. [PMID: 25655297 DOI: 10.1016/s1499-3872(14)60292-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
39 Solaini L, Sharma A, Watt J, Iosifidou S, Chin Aleong JA, Kocher HM. Predictive factors for incidental gallbladder dysplasia and carcinoma. J Surg Res 2014;189:17-21. [PMID: 24589178 DOI: 10.1016/j.jss.2014.01.064] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
40 Zhang M, Gong W, Zuo B, Chu B, Tang Z, Zhang Y, Yang Y, Zhou D, Weng M, Qin Y, Ma M, Jiang A, Ma F, Quan Z. The microRNA miR-33a suppresses IL-6-induced tumor progression by binding Twist in gallbladder cancer. Oncotarget 2016;7:78640-52. [PMID: 27769047 DOI: 10.18632/oncotarget.12693] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
41 Zhang HY, Dou KF. PCBP1 is an important mediator of TGF-β-induced epithelial to mesenchymal transition in gall bladder cancer cell line GBC-SD. Mol Biol Rep 2014;41:5519-24. [PMID: 24889597 DOI: 10.1007/s11033-014-3428-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
42 Xue Z, Yang B, Xu Q, Zhu X, Qin G. Long non-coding RNA SSTR5-AS1 facilitates gemcitabine resistance via stabilizing NONO in gallbladder carcinoma. Biochem Biophys Res Commun 2020;522:952-9. [PMID: 31810606 DOI: 10.1016/j.bbrc.2019.10.104] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Jiang TY, Feng XF, Fang Z, Cui XW, Lin YK, Pan YF, Yang C, Ding ZW, Zhang YJ, Tan YX, Wang HY, Dong LW. PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer. Cancer Lett 2021;501:187-99. [PMID: 33220333 DOI: 10.1016/j.canlet.2020.11.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Fujita T. Surgical strategy for incidental gallbladder cancer. J Am Coll Surg. 2015;220:254-256. [PMID: 25592471 DOI: 10.1016/j.jamcollsurg.2014.10.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
45 Kanthan R, Senger JL, Ahmed S, Kanthan SC. Gallbladder Cancer in the 21st Century. J Oncol. 2015;2015:967472. [PMID: 26421012 DOI: 10.1155/2015/967472] [Cited by in Crossref: 106] [Cited by in F6Publishing: 95] [Article Influence: 17.7] [Reference Citation Analysis]
46 Andrén-Sandberg A. Diagnosis and management of gallbladder cancer. N Am J Med Sci. 2012;4:293-299. [PMID: 22866265 DOI: 10.4103/1947-2714.98586] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
47 Liang PI, Li CF, Chen LT, Sun DP, Chen TJ, Hsing CH, Hsu HP, Lin CY. BCL6 overexpression is associated with decreased p19 ARF expression and confers an independent prognosticator in gallbladder carcinoma. Tumour Biol. 2014;35:1417-1426. [PMID: 24114011 DOI: 10.1007/s13277-013-1195-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
48 Huang HL, Yao HS, Wang Y, Wang WJ, Hu ZQ, Jin KZ. Proteomic identification of tumor biomarkers associated with primary gallbladder cancer. World J Gastroenterol 2014;20:5511-8. [PMID: 24833881 DOI: 10.3748/wjg.v20.i18.5511] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
49 Ruan Y, Wang L, Lu Y. HDAC6 inhibitor, ACY1215 suppress the proliferation and induce apoptosis of gallbladder cancer cells and increased the chemotherapy effect of gemcitabine and oxaliplatin. Drug Dev Res 2021;82:598-604. [PMID: 33428788 DOI: 10.1002/ddr.21780] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Zhang Y, Du P, Li Y, Zhu Q, Song X, Liu S, Hao J, Liu L, Liu F, Hu Y, Jiang L, Ma Q, Lu W, Liu Y. TASP1 Promotes Gallbladder Cancer Cell Proliferation and Metastasis by Up-regulating FAM49B via PI3K/AKT Pathway. Int J Biol Sci 2020;16:739-51. [PMID: 32071545 DOI: 10.7150/ijbs.40516] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
51 Kim JH, Lee JY, Baek JH, Eun HW, Kim YJ, Han JK, Choi BI. High-resolution sonography for distinguishing neoplastic gallbladder polyps and staging gallbladder cancer. AJR Am J Roentgenol. 2015;204:W150-W159. [PMID: 25615775 DOI: 10.2214/ajr.13.11992] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 5.2] [Reference Citation Analysis]
52 Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol 2014;6:99-109. [PMID: 24634588 DOI: 10.2147/CLEP.S37357] [Cited by in Crossref: 109] [Cited by in F6Publishing: 238] [Article Influence: 15.6] [Reference Citation Analysis]
53 Lin W, Tong C, Zhang W, Cen W, Wang Y, Li J, Zhu Z, Yu J, Lu B. Silencing ARAF Suppresses the Malignant Phenotypes of Gallbladder Cancer Cells. Biomed Res Int 2020;2020:3235786. [PMID: 32923479 DOI: 10.1155/2020/3235786] [Reference Citation Analysis]
54 Goetze TO. Gallbladder carcinoma: Prognostic factors and therapeutic options. World J Gastroenterol. 2015;21:12211-12217. [PMID: 26604631 DOI: 10.3748/wjg.v21.i43.12211] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 64] [Article Influence: 17.2] [Reference Citation Analysis]
55 Wang J, Xu C, Cheng Q, Zhao J, Wu S, Li W, Ma W, Liu C, Jiang X. RNA Sequencing Revealed Signals of Evolution From Gallbladder Stone to Gallbladder Carcinoma. Front Oncol 2020;10:823. [PMID: 32547950 DOI: 10.3389/fonc.2020.00823] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Su L, Wang MM, Xu MR, Wang X, Xia HZ, Zhang M, Zheng L, Zhu YD, Wang MQ, Li P. Banxia Xiexin Decoction () Combined with Afatinib in Treatment of Advanced Gallbladder Cancer: Case Report and Literature Review. Chin J Integr Med 2019;25:303-6. [PMID: 30707412 DOI: 10.1007/s11655-019-3152-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]